| Characteristic | Funding in million U.S. dollars |
|---|---|
| Total | 4,170 |
| HIV/AIDS | 1,269 |
| Tuberculosis | 806 |
| Malaria | 690 |
| Diarrhoeal diseases | 144 |
| Kinetoplastids | 133 |
| Dengue | 113 |
| Worms and flukes | 94 |
| Salmonella infections | 78 |
| Snakebite envenoming | 31 |
| Hepatitis B | 25 |
| Hepatitis C | 21 |
| Leprosy | 19 |
| Bacterial pneunomia/meningitis | 19 |
| Cryptococcal meningitis | 7.8 |
| Rheumatic fever | 4.9 |
| Histoplasmosis | 3.8 |
| Leptospirosis | 2.4 |
| Scabies | 1.6 |
| Buruli ulcer | 1.5 |
| Mycetoma | 0.6 |
| Platform technologies | 276 |
| Multi-disease vector control products | 55 |
| Core funding of a multidisease R&D organization | 273 |
| Other R&D | 100 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
January 2025
More information
Region
Worldwide
Survey time period
2023
Supplementary notes
Figures are in constant 2023 U.S. dollars.
Please note that some of the diseases listed above are actually groups of diseases, such as the diarrheal illnesses and helminth infections. This reflects common practice and also the shared nature of research in some areas. For example: Streptococcus pneumoniae R&D is often targeted at both pneumonia and meningitis.
Citation formats
